Small Study Offers Hope for Breast Cancer Survivors Facing Lingering Brain Fog and Exhaustion
Guest Contributor
For many people, finishing breast cancer treatment is not the end of the story. While survival rates have improved dramatically, a significant number of survivors find themselves facing a new challenge: lingering fatigue and cognitive difficulties often referred to as “brain fog after breast cancer.” These symptoms can affect memory, concentration, sleep, and energy levels, and they may persist for years after treatment ends.
Researchers and clinicians have been trying to understand why this happens and how to ease it. Treatments for breast cancer, including chemotherapy and radiotherapy, can trigger inflammation in the nervous system. This can lead to an excess of glutamate in the brain, which is thought to have neurotoxic effects and potentially contribute to cognitive impairment and fatigue. Hormone therapies, which many people continue to take for years after their initial treatment, may also play a role in these long-lasting side effects.
Against this backdrop, a small study has raised cautious hope that a nutritional supplement called oxaloacetate might help. Breast cancer is the most common cancer in women in countries such as the United Kingdom and United States, affecting around 1 in 7 to 1 in 8 women. As more people live longer after diagnosis, quality of life in survivorship has become a central concern. The idea that a supplement could support recovery from cancer-related fatigue and brain fog is therefore attracting attention.
Oxaloacetate is a compound involved in the body’s energy production processes inside cells. In this new phase 2 clinical trial, researchers explored whether it could help women who reported significant, ongoing cognitive problems after treatment for early-stage breast cancer. The study enrolled 18 women who had been diagnosed 1 to 5 years earlier and who continued to experience notable issues with thinking and memory. Their average age was 50, most had received chemotherapy, and around 90% were taking hormone therapy at the time of the trial.
Each participant was given oxaloacetate as an oral capsule. They took 500 milligrams twice a day for eight weeks. Some women experienced mild gastrointestinal side effects and two withdrew because of these symptoms, but 16 completed the full course. Throughout the study, the researchers used electronic questionnaires and cognitive tests to track changes in symptoms. These tools measured cognitive complaints, fatigue, sleep issues such as insomnia, pain, gastrointestinal problems, and health-related quality of life.
What emerged was a pattern of improvement that surprised the lead investigator, Patricia Ganz, MD, a distinguished professor at UCLA. She had initially been skeptical that oxaloacetate would offer meaningful benefits. Yet by the four-week mark, all 16 women still in the study reported better cognitive symptoms. By eight weeks, every participant showed significant gains on cognitive testing, shifting from scores that reflected impairment at the start to scores within the normal range.
The researchers documented a mean cognitive test score of 29.1 at baseline, which fell in the impaired range. After eight weeks of oxaloacetate, the mean score rose to 55.5, considered normal. Alongside this, the women reported reductions in fatigue and insomnia, and improvements in physical functioning. For some, the change was so noticeable that they chose to continue taking oxaloacetate after the trial ended with support from the company that supplied the supplement.
This study also touches on why oxaloacetate might have such effects, at least in theory. Because it is central to cellular energy metabolism, it may help the brain regulate glutamate levels. Excess glutamate is associated with neuroinflammation and potential damage to nerve cells. The authors suggest that by helping clear glutamate, oxaloacetate could moderate neuroinflammatory processes and improve how mitochondria regulate energy inside cells. In turn, that might ease fatigue and cognitive problems, although this mechanism still needs to be confirmed.
Experts urge caution, however, before anyone rushes to the supplement aisle. The study was small and did not include a comparison or placebo group, which makes it impossible to say definitively that oxaloacetate caused the improvements. There is also the possibility of a strong placebo effect, especially when people are highly motivated to feel better after a difficult illness and its demanding treatments. Kotryna Temcinaite, PhD, from the charity Breast Cancer Now, emphasized that with only 18 participants, the findings must be seen as early and exploratory.
Because supplements are not regulated in the same way as prescription medicines, questions remain about long-term safety, consistency of dosing, and how oxaloacetate might interact with ongoing cancer treatments or other medications. Temcinaite advised anyone considering supplements during or after breast cancer treatment to discuss them with their medical team first. This is especially important as many survivors are on hormone therapies for years, and any additional intervention should be evaluated in the context of their overall care.
To build a more solid evidence base, the research group is now planning a larger, randomized, placebo-controlled phase 2 trial. This next study will involve about 120 participants and will test two different doses of oxaloacetate against a placebo. To ensure that everyone in the trial has a chance to receive the active supplement, the design allows all participants eventual access to the drug. The team is also conducting animal studies to investigate the biological mechanisms more clearly, and they hope to share these findings in due course.
The lead investigator noted that it will likely take around two years to see results from the larger trial. Until then, these early findings should be seen as promising but preliminary. There is interest in whether oxaloacetate might help other cancer survivors who experience fatigue and cognitive complaints after treatment, not only those with breast cancer. For now, though, the priority is confirming that it is both effective and safe in a controlled setting.
Alongside any potential supplement, lifestyle approaches remain important. Experts highlight strategies such as pacing daily activities, integrating regular physical activity at a level that feels manageable, and eating a balanced, nutritious diet. These measures do not replace medical interventions, but they can support overall wellbeing and may help people manage the long-term effects of treatment. Recovery from breast cancer is not always a straightforward return to “normal,” and acknowledging this reality is a crucial step in providing effective, compassionate survivorship care.
I found it striking that some participants in this early trial chose to keep taking oxaloacetate once the formal study ended, which suggests that they felt meaningful changes in their daily lives. At the same time, the experts involved are clear that optimism alone is not enough, and only rigorous clinical trials can show whether this supplement truly works. For people living with brain fog and fatigue after breast cancer treatment, the hope is that ongoing research will eventually deliver clear, evidence-based options that can help them think more clearly, feel more energetic, and rebuild their lives with greater confidence.